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Abstract Recent progress in studies on apoptosis has revealed
that cytochrome c is a pro-apoptotic factor. It is released from its
places on the outer surface of the inner mitochondrial membrane
at early steps of apoptosis and, combining with some cytosolic
proteins, activates conversion of the latent apoptosis-promoting
protease pro-caspase-9 to its active form. Cytochrome c release
can be initiated by the pro-apoptotic protein Bax. This process is
blocked by the anti-apoptotic proteins Bcl-2 and Bcl-xL. The role
of cytochrome c in apoptosis may be understood within the
framework of the concept assuming that the evolutionary
primary function of apoptosis was to purify tissues from ROS-
overproducing cells. In this context, the pro-apoptosis activity of
cytochrome c might represent one of the anti-oxidant functions
inherent in this cytochrome. Among other cytochrome c-linked
antioxidant mechanisms, the following systems can be indicated.
(1) Cytochrome c released from the inner mitochondrial
membrane to the intermembrane space can operate as an enzyme
oxidizing O3c2 back to O2. The reduced cytochrome c is oxidized
by cytochrome oxidase (or in yeasts and bacteria, by cytochrome
c peroxidase). (2) The intermembrane cytochrome c can activate
the electron transport chain in the outer mitochondrial mem-
brane. This bypasses the initial and middle parts of the main
respiratory chain, which produce, as a rule, the major portion of
ROS in the cell. (3) The main respiratory chain losing its
cytochrome c is inhibited in such a fashion that antimycin-like
agents fail to stimulate ROS production.
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1. Introduction
In 1996 I considered possible reasons why mitochondria are
involved in apoptosis [1]. It was assumed that the pro-
grammed cell death (apoptosis) was invented by biological
evolution as a mechanism to purify the cell population from
ROS-overproducing cells. Since mitochondria are usually the
main source of ROS in the cell, it is not surprising that they
are involved in apoptosis, being equipped with pro-apoptotic
proteins. Apoptosis-inducing factor (AIF), an ICE-like pro-
tease, is one of them [2^4]. AIF is localized in the mitochon-
drial intermembrane space. It is released to the cytosol due to
breakdown of the outer membrane of mitochondria when the
permeability transition pore (PTP) is opened.
The PTP is known to be induced by ROS. This may rep-
resent a mechanism of induction of ROS-linked apoptosis.
Other PTP inducers are also apoptogenic, while PTP inhibi-
tors are anti-apoptotic, a fact indicating that di¡erent tissue
functions requiring apoptosis may be realized via similar
mechanisms [3,4].
In 1996^1997, one more pro-apoptotic protein was identi-
¢ed in mitochondria. This proved to be cytochrome c, a well
known component of the mitochondrial respiratory chain. In
this paper I shall summarize related observations, trying to
answer the question why evolution selected cytochrome c for
this role. In this connection, various possible antioxidant ef-
fects of cytochrome c will be considered.
2. Cytochrome c mediates apoptosis
Cytochrome c is a small (in mammals, 104 amino acid
residues), very stable hemoprotein containing covalently
bound heme c as a prosthetic group. Its sequence and the
three-dimensional structure at atomic resolution have been
known for many years. It was also shown that cytochrome
c is bound to the outer surface of the inner mitochondrial
membrane. As for the function of cytochrome c, biochemists
believed that it is rather simple, namely to transport electrons
from cytochrome c1 to cytochrome oxidase. This transport
per se is not coupled to energy transduction so the role of
cytochrome c seems to be restricted to the function of a shut-
tle connecting two respiratory chain energy transducers, i.e.
the bc1 complex (complex III) and cytochrome oxidase (com-
plex IV) (for review, see [5]).
The dogma of apparent simplicity of the cytochrome c
function was shaken in 1996 when Wang and co-workers [6]
discovered that this protein is somehow involved in apoptosis.
As a model of apoptosis, treatment of cell-free extract from
HeLa cells with dATP was used. It was found that the addi-
tion of dATP to the extract resulted in typical apoptotic
changes, i.e. (i) cleavage of the caspase-3 precursor yielding
active caspase-3 (an apoptosis-linked protease), (ii) nuclear
DNA fragmentation and (iii) speci¢c morphological changes
in the cell nucleus. Fractionation of the extract revealed the
existence of at least two factors necessary to the above e¡ect.
Cytochrome c proved to be one of them. In other experiments
it was shown that treatment of HeLa cells with staurosporine,
a potent pro-apoptotic agent, causes release of cytochrome c
from mitochondria to cytosol. Similar relationships were re-
vealed in human embryonic and monoblastic cell lines.
In 1997, the above observations were con¢rmed and ex-
tended by Wang’s [7] and Newmeyer’s [8,9] groups. It ap-
FEBS 19829 25-2-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 0 6 1 - 1
*Fax: (7) (95) 939 03 38 or (7) (95)939 31 81.
E-mail: skulach@head.genebee.msu.su
Abbreviations: vWH , transmembrane electrochemical H
 potential
difference; v8, transmembrane electric potential difference; AIF,
apoptosis-inducing factor; Apaf-1 and Apaf-3, apoptosis-activating
factors 1 and 3; ICE, interleukin-converting enzyme; PTP, perme-
ability transition pore; ROS, reactive oxygen species; Z-VAD-fmk,
carbobenzoxy-Val-Ala-Asp-fluoromethylketone
FEBS 19829 FEBS Letters 423 (1998) 275^280
peared that staurosporine-induced release of cytochrome c to
cytosol of human acute myeloid leukemia cells is blocked by
overexpression of the anti-apoptotic Bcl-2 protein which is
present in the outer mitochondrial membrane [7]. Moreover,
it was found that cytochrome c did not leave mitochondria
treated with hypotonic (150 mM) sucrose provided that the
Bcl-2 superproducing cell line was used [7].
Newmeyer’s group has reported the release of cytochrome c
from mitochondria of the CEM cell line treated with some
apoptogens (ultraviolet treatment, etoposide, staurosporine,
actinomycin D or H2O2) and its retention in the Bcl-2-over-
producing line. Moreover, addition of the baculovirus-ex-
pressed Bcl-2 to Xenopus egg mitochondria slowed down the
release of cytochrome c from these mitochondria incubated in
the presence of cytosol. The caspase-3 activation by combined
action of a cytosolic fraction and puri¢ed cytochrome c was
con¢rmed [8]. Cytochrome c preparations from various verte-
brate species, but not from Saccharomyces cerevisiae, were
able to initiate all signs of apoptosis. Cu- and Zn-substituted
cytochrome c had strong pro-apoptotic activity although they
were inactive as electron carriers [9].
Quite recently, Wang and co-authors [10,11] identi¢ed the
cytosolic partner of cytochrome c in the apoptotic cascade.
This proved to be a protein showing signi¢cant sequence ho-
mology to Ced-4, a Caenorhabditis elegans factor activating
pro-caspase-3. The protein, called apoptosis-activating factor
1 (Apaf-1), possesses a nucleotide binding site apparently re-
sponsible for binding of dATP, a cofactor of apoptosis. It was
shown that addition of (i) Apaf-1, (ii) cytochrome c (previ-
ously Apaf-2) and (iii) dATP to pro-caspase-9 (previously
Apaf-3) results in conversion of pro-caspase-9 to active cas-
pase-9. Caspase-9 causes cleavage of pro-caspase-3 to caspase-
3, the key enzyme involved in apoptosis (see below, Fig. 1).
In the above mentioned publications of Wang and New-
meyer, it was stressed that cytochrome c release from mito-
chondria is not accompanied by a mitochondrial v8 collapse
[7,8]. On the other hand, Wang and coworkers [12] showed
that apoptosis induced by the anticancer drug arabinosylcy-
tosine (Ara-C) in human myeloid leukemia HL-60 cells, also
related to cytochrome c release, causes the loss of v8. All
these e¡ects were inhibited by overexpression of Bcl-xL, a
very close relative of Bcl-2, possessing, like Bcl-2, anti-apop-
totic activity.
According to Wang and Studzinski [13], in the same type of
cells the apoptosis-inducing release of cytochrome c is blocked
by 1,2,5-dihydroxyvitamin D3. The e¡ect was shown to be
mediated by the anti-apoptotic protein Mcl-1 rather than by
Bcl-2 or Bcl-xL. The vitamin increased in mitochondria the
levels of Mcl-1 as well as of the proliferation-associated pro-
tein Raf-1.
Kufe and his colleagues [14] reported that a human myeloid
leukemia line overexpressing Bcl-xL failed to (i) release cyto-
chrome c from mitochondria to cytosol and (ii) undergo apop-
tosis in response to such apoptogenic treatment as ionizing
radiation. Further analysis revealed the existence of a complex
of Bcl-xL and cytochrome c both in the irradiated and in non-
treated cells. No such complex was found when pro-apoptotic
Bcl-xS, a Bcl-xL derivative of a shorter length, was studied. A
complex of Bcl-xL and cytochrome c was also found when
puri¢ed recombinant hexa-His-Bcl-xL bound to a nitrocellu-
lose ¢lter was treated with bovine heart cytochrome c for 1 h.
In this system, Bcl-xS was found to prevent formation of the
Bcl-xL-cytochrome c complex. Experiments using an immuno-
gold labeling method have localized Bcl-xL to mitochondria in
the Bcl-xL-overproducing cells.
Independently, Manon and co-authors [15] analyzed yeast
cells expressing human Bcl-xL and Bax, another member of
the Bcl-2 family which, like Bcl-xS, shows pro-apoptotic ac-
tivity. In the Bax-expressing cells, two e¡ects were found,
namely a decrease in the amount of cytochrome oxidase and
a dramatic release of cytochrome c to the cytosol. On the
other hand, the bc1 complex and H-ATPase were una¡ected.
Coexpression of Bcl-xL almost fully prevented the e¡ects of
Bax.
In 1996, the X-ray structure of Bcl-xL was published by
Muchmore et al. [16]. It proved to be strikingly similar to
the pore-forming subunit of diphtheria toxin, which trans-
ports the ADP-ribosylating subunit of the toxin across the
cell membrane (for discussion, see [17]). In 1997, it was re-
ported that both anti- and pro-apoptotic proteins (Bcl-2, Bcl-
xL [18,19] and Bax [17,19], respectively) can form 20^300 pS
single channels in model planar phospholipid membranes.
Under some conditions, the channels become much larger
(s 1 nS) [17,19]. Bcl-2 and Bax showed mild cation and anion
selectivities, respectively. The PK=PCl3 values were 2.4 for
Bcl-2 and 0.32 for Bax [19]. Incorporation of both proteins
into the membrane took place at acidic pH only (just as in the
case of diphtheria toxin) [19].
The X-ray and planar membrane data may be of crucial
importance for understanding the whole Bcl-2 story. Let us
assume that pro-apoptotic members of the Bcl-2 family such
as Bcl-xS or Bax allow cytochrome c to escape from the mi-
tochondrial intermembrane space. This might be done by for-
mation of a cytochrome c-speci¢c transport pathway includ-
ing (i) loose binding of cytochrome c with, e.g., Bax on the
inner surface of the outer mitochondrial membrane, (ii) its
translocation across the membrane via the diphtheria toxin-
like part of Bax, and (iii) release of cytochrome c on the outer
surface of the outer membrane. However, according to P.
Nicotera (personal communication), not only cytochrome c
but also adenylate kinase is released from the mitochondrial
intermembrane space at an early step of apoptosis. Thus Bax
apparently forms a non-speci¢c large pore permeable for pro-
teins. It is also possible that Bax breaks down the outer mi-
tochondrial membrane, directly a¡ecting it like digitonin or
forming pores in the inner membrane, resulting in swelling of
the mitochondrial matrix and, as a consequence, in disruption
of the outer membrane.
As for the anti-apoptotic proteins (Bcl-2, Bcl-xL), they fail
to permeabilize the outer membrane for cytochrome c but can
tightly bind this cytochrome. In other words, their membrane-
a¡ecting activity seems to be suppressed whereas the cyto-
chrome c binding activity is increased compared with pro-
apoptotic members of the same protein family.
Apparently both the pro- and anti-apoptotic proteins in
question are competent in formation of oligomers (this e¡ect
might be essential for formation of a large channel). Since all
of them are rather similar structurally, heterogenic oligomers
(e.g. containing Bcl-2 and Bax) can also be formed. The
oligomer-forming partners are inactive. This could explain
the Bax-Bcl-2 crosstalk (e.g. [15]).
The real situation appears to be even more complex if we
take into account that mechanisms of apoptosis may, to some
degree, depend upon the type of the apoptosis-inducing stim-
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ulus. Gottlieb and coworkers [20,21] reported that apoptosis
caused by antibodies to Fas protein, in contrast to that caused
by H2O2, staurosporine and some other stimuli used by Wang
and Newmeyer, is not accompanied by cytochrome c release
from mitochondria. Nevertheless, mitochondrial respiration is
blocked at the cytochrome c level. The inhibition seems to be
induced by the so-called post-mitochondrial fraction whose
activity (i) was arrested by an ICE-protease inhibitor, carbo-
benzoxy-Val-Ala-Asp-£uoromethylketone (Z-VAD-fmk), and
(ii) required the outer mitochondrial membrane to be permea-
bilized by digitonin or the incubation medium to be acidi¢ed
to pH 6.8. Addition of cytochrome c to the digitonin-treated
mitochondria, inhibited by the ‘post-mitochondrial fraction’,
restored the normal respiration rate.
Unfortunately, the nature of the respiration-inhibiting fac-
tor(s) remain obscure. The above-mentioned ‘post-mitochon-
drial fraction’ was prepared as follows. Homogenate obtained
by nitrogen cavitation of Jurkat cells suspended in a solution
of 100 mM sucrose, 5% Percoll and some other ingredients,
was centrifuged at 2500Ug for 5 min. Centrifugation of the
2500Ug supernatant (10 000Ug, 15 min) provided (i) a pellet
called ‘mitochondrial fraction’ and (ii) the supernatant (‘post-
mitochondrial fraction’). The ‘mitochondrial fraction’ was
found to contain about two thirds of the cytochrome oxidase
pool of the homogenate whereas one third of it was localized
in the ‘post-mitochondrial fraction’. This means that the
‘post-mitochondrial fraction’ contained a rather large portion
of the mitochondrial inner membranes, most probably as
swollen (‘light’) mitochondria which did not precipitate at
10 000Ug in the sucrose-Percoll medium used.
Further studies of the same group showed that the ‘post-
mitochondrial fraction’ from CEM cells that overexpress Bcl-
2 both prevents and reverses inhibition of mitochondrial res-
piration by the ‘post-mitochondrial fraction’ from Fas anti-
body-treated Jurkat cells [21]. This reversibility indicates that
in the inhibited mitochondria, cytochrome c does not go far
from the inner mitochondrial membrane. One possibility is
that it is released from the outer surface of the inner mem-
brane, crosses the intermembrane space and combines with
Bax on the inner surface of the outer membrane.
It should be stressed that the e¡ect described by Gottlieb’s
group represents a very early apoptotic event. A 5 min treat-
ment of the Jurkat cells with anti-Fas antibodies proved to be
su⁄cient to initiate some inhibitory activity of the ‘post-mi-
tochondrial fraction’ [21].
Release of cytochrome c to cytosol might be the next step
of the process. Formally speaking, this speculation is incon-
sistent with the facts that Z-VAD-fmk fails to prevent cyto-
chrome c release to cytosol [8] whereas respiratory inhibition
by the ‘post-mitochondrial fraction’ is abolished by this pro-
tease inhibitor [21]. However, this discrepancy may be due to
the fact that di¡erent apoptogenic stimuli were used by Kluck
et al. [8] and Adachi et al. [21]. The role of the Z-VAD-fmk-
sensitive protease is unclear. This is hardly hydrolysis of the
cytochrome c polypeptide chain since (i) the inhibition of
respiration is reversible [21] and (ii) the spectrum of cyto-
chrome c in the inhibited mitochondria is not changed [20].
It seems possible that the above protease is identical to AIF
which is also sensitive to Z-VAD-fmk [3,4]. AIF has been
shown to be released from mitochondria due to swelling
caused by the PTP opening [2^4] so the fraction of light mi-
tochondria could be the source of AIF. An e¡ect of AIF
added to mitochondria was already described by Kroemer’s
group. It was found that the added AIF stimulates the open-
ing of the PTP [4].
3. Place of cytochrome c in the antioxidant system of the cell
As already mentioned in Section 1, apoptosis can be initi-
ated by an increase in the concentration of ROS (for reviews,
see [22,23]). Apparently, for aerobic organisms, ROS-linked
apoptosis is the last line of antioxidant defence at the cellular
level. This process was postulated to purify the cell population
from those cells which proved to be dangerous for the tissue
since they become, for some reason, ROS superproducers [22^
24]. Since mitochondria generate, as a rule, the main portion
of ROS in the cell [1,22^24], it is not surprising that AIF, for
example, specialized in mediating apoptosis, is localized in
mitochondria. As for cytochrome c, it originally specialized
in a function other than apoptosis. Nevertheless, its role in
this process may, in my opinion, be understood within the
framework of the same antioxidant concept.
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Fig. 1. Possible role of cytochrome c in the antioxidant defence sys-
tem of mitochondria and in apoptosis. I, III and IV, corresponding
respiratory chain complexes (NADH-CoQ reductase, CoQH2-cyto-
chrome c reductase and cytochrome c oxidase, respectively); c and
b5, cytochrome c and cytochrome b5, respectively; Fp5, NADH-cy-
tochrome b5 reductase; Bcl-2 and Bax, anti- and pro-apoptotic pro-
teins of the Bcl-2 family, respectively; Apaf-1, apoptosis-activating
factor 1. It is assumed that cytochrome c, desorbed from the inner
mitochondrial membrane to the intermembrane space, oxidizes
superoxide which is produced by complexes I and III. Moreover, it
receives electrons from an external respiratory chain (Fp5 and b5)
localized in the outer mitochondrial membrane, bypassing the O3c2 -
producing complexes I and III. Cytochrome c reduced by O3c2 or by
b5 is reoxidized by cytochrome oxidase or cytochrome c peroxidase.
If these mechanisms fail to prevent large-scale O3c2 production, Bax-
mediated release of cytochrome c to the cytosol is assumed to be in-
itiated. This release may be due to cytochrome c translocation by
Bax or, more probably, to the Bax-mediated disruption of the outer
mitochondrial membrane. Cytosolic cytochrome c activates the
apoptotic cascade so the O3c2 -superproducing cell is discarded by
apoptosis. To simplify the scheme, I did not show the ROS-induced
PTP opening and mitochondrial swelling, the event also resulting in
disruption of the outer membrane of mitochondria. AIF, another
intermembrane pro-apoptotic protein, is also omitted. It is shown
that Bcl-2 combines with Bax and inactivates it. Moreover, Bcl-2
may apparently attenuate apoptosis by (i) preventing opening of the
PTP and (ii) binding of released cytochrome c.
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The role of cytochrome c in the antioxidant system of mi-
tochondria and in apoptosis is illustrated in Fig. 1. The fol-
lowing processes possibly involved in the cytochrome c-linked
defence mechanism are indicated in the ¢gure.
(1) Oxidation by cytochrome c of superoxide which is gen-
erated by complexes I and III of the respiratory chain. As a
result cytochrome c is reduced and O3c2 is converted back to
O2. The reduced cytochrome c is then oxidized by complex
IV, resulting in the formation of H2O from O2.
In yeast, cytochrome c peroxidase localized in the inter-
membrane space [25] can substitute for cytochrome oxidase
as oxidant of the O3c2 -reduced cytochrome c. This enzyme is
also found in the periplasmic space of some aerobic bacteria
(for references, see [26]). The cytochrome c-cytochrome c per-
oxidase system appears to be a scavenger simultaneously for
both O3c2 and H2O2 :
2Cyt:c3  2O3c2 !2Cyt:c2  2O2 1
2Cyt:c2 H2O2  2H!2Cyt:c3  2H2O 2
In an anaerobically grown, respiratory chain-de¢cient mu-
tant of yeast, lacking cytochrome c, cytochrome c peroxidase
and other respiratory enzymes, aeration results in immediate
and speci¢c induction of synthesis of cytochrome c and cyto-
chrome c peroxidase. Later catalase is also induced [27^29].
The ability of soluble cytochrome c to oxidize O3c2 to O2 is
widely used by researchers as a method of O3c2 measurement.
Apparently, to oxidize O3c2 at a high rate in mitochondria,
cytochrome c should be released to the intermembrane solu-
tion. As for cytochrome c bound to complexes III or IV, it is
hardly competent in fast oxidation of O3c2 just as of ascorbate,
another hydrophilic reductant of soluble cytochrome c. In line
with this suggestion, we recently found that addition of cyto-
chrome c to mitochondria in the resting state (state 4) strongly
suppresses the formation of H2O2 (R.A. Simonyan, V.P. Sku-
lachev and A.A. Starkov, in preparation).
(2) The cytochrome c-mediated oxidation of external NADH
by complex IV via NADH-cytochrome b5 reductase and cyto-
chrome b5. This energy non-coupled pathway localized in the
outer mitochondrial membrane (for review, see [1]) bypasses
the initial and middle segments of the respiratory chain which
produce O3c2 in state 4 where ADP is exhausted [30]. Just these
segments are known to be targets for antimycin A, rotenone
and a large number of hydrophobic xenobiotics. Inhibition of
the respiratory chain by these agents strongly increases O3c2
production by mitochondria [22,30^32]. Activation of the ex-
ternal electron transport pathway overcomes the inhibition
and, hence, should decrease the O3c2 formation.
Release of cytochrome c to the intermembrane space of
liver mitochondria caused by cold exposure of rats was de-
scribed in our group by Mokhova and co-authors [33,34].
This observation exempli¢es the case when mitochondria in
vivo regulate a⁄nity of cytochrome c to the inner membrane
respiratory chain complexes and its concentration in the in-
termembrane space.
The cytochrome b5-mediated electron transport pathway is
inherent in liver and, to a lesser degree, in kidney and some
other tissues. It is absent from muscles which possess another
non-coupled external NADH oxidation system of unknown
mechanism (for review, see [5]).
(3) The cytochrome c desorption to the intermembrane space
can decrease the superoxide production activated by inhibition
of the respiratory chain at the antimycin A-sensitive site. This
e¡ect was ¢rst described by Turrens et al. [35] and was re-
cently reproduced in this group (Simonyan and Starkov, un-
published). It can be explained by inhibition of oxidation of
the complex III FeS cluster (and, hence, inhibition of the
CoQH2 oxidation to CoQHc) due to removal of cytochrome
c from the inner membrane. This e¡ect resembles the myxo-
thiasol inhibition of O3c2 generation in antimycin A-treated
mitochondria [22,32].
(4) The Bax- or/and PTP-mediated release of cytochrome c
to the cytosol, in cooperation with some cytosolic factors, in-
duces apoptosis. It is not clear yet whether the e¡ect of Bax
could be triggered by an increase of the ROS concentration in
the cell. However, it has already been proved that ROS induce
opening of the PTP (for reviews, see [22,23,36]) and Bcl-2
inhibits this e¡ect [4].
Cytosolic cytochrome c can, in principle, be reduced by O3c2
in the cytosol and then can be oxidized by cytochrome oxidase
provided that the outer mitochondrial membrane is broken or
cytochrome c-permeable. However, this process is apparently
of low rate because of great dilution of cytochrome c in the
cytosol.
Desorption of cytochrome c from the inner mitochondrial
membrane is of crucial importance for the scheme shown in
Fig. 1. This process was found in our group to occur under
some physiological conditions related to stimulation of oxida-
tive metabolism. In liver, this takes place in response to cold
exposure of rats (see above). Interestingly, this process is
greatly stimulated by thyroid hormones [34]. According to
our hypothesis [22^24,37], thyroid hormones stimulate the
antioxidant system of the cell to compensate for an increase
in ROS production due to up-regulation of respiratory metab-
olism which is induced by the same hormones. The following
potential antioxidant e¡ects of thyroid hormones can be men-
tioned:
1. Increase in non-ohmicity of the inner mitochondrial
membrane (e¡ect of mild uncoupling occurring at high
vWH ) [38,39] which should prevent a strong increase in
the rate of ROS production by mitochondria in the rest-
ing state [30]. At least partially this e¡ect may be due to
induction by thyroid hormones of synthesis of (i) the
uncoupler protein-2 [40] and (ii) the mitochondrial
ATP/ADP antiporter [41], an anion carrier involved in
uncoupling by fatty acids [5,42^44].
2. The PTP opening in a cyclosporin A-insensitive fashion
[45].
3. Induction of synthesis of mitochondrial K-glycerophos-
phate dehydrogenase [46,47] and cytosolic malic enzyme
[46,48], events stimulating the £ux of reducing equiva-
lents from mitochondria to cytosol and a bypass of ini-
tial steps of the coupled respiratory chain (complex I)
which is especially active in generation of ROS.
4. Induction of synthesis of cytochrome c [49]. This e¡ect is
strong in liver and less strong in kidney, which correlates
with the amount of cytochrome b5 in these tissues.
Stimulation of release of the membrane-bound cytochrome
c to the intermembrane space [34] might represent one more
antioxidant e¡ect of thyroid hormones.
In conclusion, the pro-apoptotic e¡ect of cytochrome c may
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be regarded as one of the antioxidant functions inherent in
this protein. This can explain why cytochrome c proved to be
involved in apoptosis. An alternative possibility is that cyto-
chrome c was randomly selected by evolution as a mitochon-
drial pro-apoptotic factor.
4. Addendum
Quite recently Vander Heiden et al. [50] reported in Cell
that not only staurosporine but also anti-Fas antibodies cause
release of all the cytochrome c pool from mitochondria to
cytosol. This observation contradicts the above-mentioned
publication of Gottlieb’s group. The reason for this discrep-
ancy is unclear.
In the same paper [50], it was reported that Bcl-2 com-
pletely prevents the cell death induced by oligomycin and
antimycin A treatments. Inhibition of respiration by these
two agents was not a¡ected by Bcl-xL although Bcl-xL pre-
vented release of cytochrome c. This means that oligomycin
and antimycin A kill the cell indirectly, due to induction of
apoptosis rather than directly, i.e. because of inhibition of
H-ATPase and complex III, respectively. The well-known
ability of oligomycin and antimycin A to increase the ROS
production by mitochondria may give rise to apoptosis in
these experiments.
According to Vander Heiden et al. [50], apoptosis allows
antibodies to subunit IV of cytochrome oxidase to reach their
target which is unavailable in control cells. This fact points to
disruption of the outer mitochondrial membrane in apoptotic
cells.
Unfortunately the authors of this interesting publication
tried to measure mitochondrial v8, using rhodamine-123 in
all the experiments shown in the ¢gures. This probe, in con-
trast to another probe JC-1, fails to monitor mitochondrial
v8 in intact cells [51]. As a results, the authors came to some
confusing conclusions (like the assumption that ‘‘Bcl-2 T reg-
ulates the accumulation of hydrogen ions in the intermem-
brane space’’ (by forming ‘‘an ion channel in the outer mem-
brane’’), etc.
These conclusions were used by Reed in the same issue of
Cell [52] as a basis for the hypothesis that the pro-apoptotic
Bax activates K in£ux into mitochondria via the K
uniporter whereas the anti-apoptotic Bcl-xL prevents K
in£ux by activating the K/H antiporter. However, there is
no evidence that the above-mentioned porters are really in-
volved. Even more, cooperation of the K uniporter and the
K/H antiporter must result in complete uncoupling and
collapse of v8, which hardly occurs in the Bcl-xL-overproduc-
ing cells.
In his article, Reed also mentioned that ‘‘experiments using
irreversible pan-caspase inhibitory peptides have provided evi-
dence that apoptosis induced by growth factor deprivation,
anticancer drugs, and Bax overexpression is potentially inhib-
ited when caspases are inactivated but cell death is not
stopped. Under these circumstances, cytochrome c is still re-
leased, v8 drops, ROS are generated and the cell dies by a
caspase-independent mechanism that resembles necrosis. Thus
release of cytochrome c from mitochondria has two ways of
killing cells: (a) by activating caspases via Apaf-1, and (b) by
interrupting electron transport chain, thus preventing oxida-
tive phosphorylation, promoting free-radical production, and
eventually depriving the cell of ATP’’ [52]. This means that we
should distinguish two cytochrome c-related phenomena:
1. Immediate e¡ects of release of cytochrome c from the
inner mitochondrial membrane, an event decreasing, as
we suggest, the level of ROS; if, nevertheless, the ROS
level increases, it causes apoptosis provided that caspase
activation is possible.
2. Remote consequences of the respiratory chain inhibition
due to cytochrome c release.
In case (2) an increase in ROS formation may occur due to
inhibition of respiration and exhaustion of energy sources
supporting maintenance of high levels of antioxidants in the
cell.
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